CAPĀ® for Vaccine Production

CAP® cells are highly advantageous in the field of vaccine production:

Stable CAP® cells are derived from primary human amniocytes and meet highest ethical standards. They are of non-tumor origin, obtained under guidance of ethical committees and with complete informed consent of the donor. From first cultivation of primary cells up to Master Cell Bank every  step is fully documented.


CAP® cells grow to very high cell densities in suspension culture and allow upscaling to all relevant bioreactor formats in chemically defined medium. Thus and in contrast to most other production cell lines, vaccines can be produced in chemically defined, serum-free media.

CAP® cells  produce high virus titers upon infection with e.g. Influenza virus, Polio virus, Adenovirus or  Retroviruses and allow the production of efficient protective vaccines like e.g. human HCMV dense bodies vaccine.

For further information, please contact us at: